



Supplementary material

Supplementary Figure 1	4
Supplementary Figure 2	6
Supplementary Figure 3	8
Supplementary Figure 4	11
Supplementary Figure 5.	12
Supplementary Figure 6	12
Supplementary Figure 7.	13
Supplementary Figure 8.	14
Supplementary Figure 9	15
Supplementary Figure 10	16
Supplementary Figure 11.	17
Supplementary Figure 12	18
Supplementary Table 1.....	19


A




W259G




V238T




F350Y




W259G/V238T



W259G/F350Y




F350A



F350T




F350V



W259G/V238T/F350A




W259G/V238T/F350T




W259G/V238T/F350V


B



MSACL WT




W259G




W259G/V238T

Supplementary Figure 1. SDS gel using the Nu-PAGE system (Invitrogen) of the MSACL WT and mutants. M: Molecular marker SeeBlue® Plus2 pre-stained standard (6 μ l deposited), I: Induction (15 μ g deposited), L: lysate (supernatant, 15 μ g deposited), FT: Flow Through NiNTA (15 μ g deposited) and P: purified enzyme (5 μ g deposited). **A.** Small-scale purification. **B.** Large-scale purification.


A



B




C




Supplementary Figure 2. UHPLC-MS (APCI) chromatograms and product mass spectra of blank reaction mixture without enzyme (blue) and reaction mixtures (black) of **A.** 4-aminobutyric acid and wild-type *MsACL*; MS: extraction of the mass $m/z = 86$ from the Total Ion Current (TIC) signal, $t_r = 2.3$ min. **B.** 5-aminovaleric acid and *MsACL* F350Y; MS: extraction of the mass $m/z = 100$ from the TIC signal, $t_r = 3.0$ min. **C.** 6-aminohexanoic acid and *MsACL* W259G; MS: extraction of the mass $m/z = 114$ from the TIC signal, $t_r = 3.4$ min.


A





B




C




Supplementary Figure 3. UHPLC-MS (APCI) chromatograms and product mass spectra of standard product of **A.** 4-aminobutyric acid; MS: extraction of the mass $m/z = 86$ from the TIC signal, $t_r = 2.3$ min. **B.** 5-aminovaleric acid; MS: extraction of the mass $m/z = 100$ from TIC signal, $t_r = 3.0$ min. **C.** 6-aminohexanoic acid; MS: extraction of the mass $m/z = 114$ from the TIC signal, $t_r = 3.4$ min.



A**B**

C




D




E**F**

Supplementary Figure 4. UHPLC-MS (ESI) chromatograms of reaction mixture of various carboxylic acids with *N*-methyl amine and MsACL WT and mutants. **A.** *N*-methylbutyramide. **B.** *N*-methylpentanamide. **C.** *N*-methylhexanamide. **D.** *N*-methylheptanamide. **E.** *N*-methyloctanamide. **F.** *N*-methyldecanamide.




Supplementary Figure 5. Michaelis-Menten plot for the determination of the kinetic parameters of *MsACL* wild-type.

Reactions conditions: TRIS pH 7.5; ATP 0-10 mM; 4-aminobutyric acid 10 mM; *MsACL* wild-type 0.5 mg/mL.



Supplementary Figure 6. Michaelis-Menten plot for the determination of the kinetic parameters of *MsACL* W259G. Error represent standard deviations from two independent experiments. The uncertainties of the kinetic parameters values are those generated by the fitting.

TRIS pH 7.5; ATP 10 mM; 6-aminohexanoic acid 6 M; *MsACL* W259G 0.05 mg/mL.




Supplementary Figure 7. Michaelis-Menten plot for the determination of the kinetic parameters of MSACL W259G/V238T. Error represent standard deviations from two independent experiments. The


Uncertainties of the kinetic parameters values are those generated by the fitting.

TRIS pH 7.5; ATP 10 mM; 6-aminohexanoic acid 6 M; MsACL mutant W259G/V238T 0.05 mg/mL.

A




B




Supplementary Figure 8. NMR spectra of standard *N*-methylhexanamide in CDCl₃. **A.** ¹H 600 MHz. **B.** ¹³C 125 MHz.

A




B




Supplementary Figure 9. NMR spectra of standard *N*-methylheptanamide in CDCl₃. **A.** ¹H 600 MHz. **B.** ¹³C 125 MHz.


A




B



Supplementary Figure 10. NMR spectrum of standard *N*-methyloctanamide in CDCl₃. **A.** ¹H 600 MHz. **B.** ¹³C 125 MHz.



Supplementary Figure 11. Analytical yields of lactam formation from ω -amino acids catalyzed by WT and mutant enzymes. **A.** γ -butyrolactam. **B.** δ -valerolactam. **C.** ϵ -caprolactam. The dotted red line indicates the yield of spontaneous cyclisation. Reaction conditions: 5 mM ω -amino acid (**1-3**), 5 mM ATP, 5 mM MnCl_2 in 50 mM MOPS buffer (pH 8.5), 2 mg/mL of purified enzyme, 400 rpm at 60 °C for 24 h. Control reactions correspond to samples without enzyme. Analytical yields were deduced from calibration curves by UHPLC-MS (APCI).



Supplementary Figure 12. Comparison of the relative areas of various substrates compared to the best variant enzyme for each substrate by monitoring the formation of the corresponding N-methyl amide compounds by UHPLC-MS. Reaction conditions: 5 mM substrate (**4-6**; **8-9**; **10-14**), 5 mM ATP, 5 mM MgCl₂, 50 mM MeNH₂ in 50 mM phosphate buffer (pH 8) was added 0.2 mg/mL of purified enzyme, 400 rpm at 60 °C for 24 h.

Supplementary Table 1. Primer sequence for variant. Mutated codons are in bold and underlined.

A4YDT1 variant	Primer	Sequence
W259G	Forward (F)	TGGGCCAAGTTCGCG <u>GGC</u> AGCTCATTCTTCTCTCCCCTT
	Reverse (R)	AAGGGGAGAGAAGAATGAGCT <u>GCCC</u> GCGAACTTGGCCCA
V238T	Forward (F)	ACCACAGCCTCCATA <u>ACC</u> GGCGTCAGGGAGAGCGATCTCCACTTA
	Reverse (R)	TAAGTGGAGATCGCTCTCCCTGACGCC <u>GGT</u> TATGGAGGCTGTGGT
F350Y	Forward (F)	CTTACCATAAGGGACT <u>TAT</u> TACGGCCAGACTGAGACC
	Reverse (R)	GGTCTCAGTCTGGCCGT <u>ATA</u> GTCCCTTATGGTAAG
F350A	Forward (F)	CTTACCATAAGGGAC <u>GCCT</u> TACGGCCAGACTGAGACC
	Reverse (R)	GGTCTCAGTCTGGCCGT <u>GGC</u> GTCCCTTATGGTAAG
F350T	Forward (F)	CTTACCATAAGGGAC <u>ACCT</u> TACGGCCAGACTGAGACC
	Reverse (R)	GGTCTCAGTCTGGCCGT <u>GGT</u> GTCCCTTATGGTAAG
F350V	Forward (F)	CTTACCATAAGGGAC <u>GTGT</u> TACGGCCAGACTGAGACC
	Reverse (R)	GGTCTCAGTCTGGCCGT <u>CAC</u> GTCCCTTATGGTAAG